Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
This was 4 months ago
Locationonline
ProgrammesThe diversification of battery technologies is opening the market to more applications and alternatives for energy storage, while promising greater efficiency and environmental sustainability.
How will next-generation batteries redefine energy storage? What breakthroughs in sodium-ion and solid-state batteries, both lithium- and sodium-based, are set to revolutionise electrification?
Discover how these advanced technologies promise to transform industries – from extending the range and safety of electric vehicles to powering the future of electric airplanes or advancing energy storage solutions. Gain insights into both the technological advancements and the commercial implications of these innovations.
More information and registration : here
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI, data & cloud Deployment: Best use of technologies
Security AI, data & cloud Cybersecurity Defence Space
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.